Saturday 17 October 2026
Export EW’s income statement to Excel — free account
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS fell 26.3%, free cash flow grew 142.8% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.
86.60
1.50
−1.70%
Follow EW
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
33.38 | 46.33 | 42.37 | 51.99 |
P/S ratio |
7.73 | 8.22 | 7.36 | 8.01 | |
P/FCF ratio |
58.73 | 38.20 | 43.78 | 37.15 | |
P/Operating CF |
79.26 | 110.57 | 1,058.96 | 79.98 | |
P/B ratio |
4.46 | 4.82 | 4.49 | 4.86 | |
Price to Tangible BV |
6.22 | 6.70 | 6.37 | 7.05 | |
EV/Sales |
7.28 | 7.72 | 6.97 | 7.54 | |
EV/EBITDA |
27.07 | 32.96 | 29.12 | 30.40 | |
EV/Operating CF |
42.12 | 29.35 | 32.32 | 28.53 | |
EV/FCF |
55.32 | 35.88 | 41.44 | 34.97 | |
Quick Ratio |
2.98 | 2.83 | 3.30 | 3.45 | |
Current Ratio |
4.00 | 3.72 | 4.42 | 4.52 | |
Net Debt/EBITDA |
(9.37) | (18.72) | (5.93) | (6.57) | |
Debt/Assets |
4.51% | 4.37% | 4.49% | 4.32% | |
Debt/Equity |
0.06 | 0.06 | 0.06 | 0.06 | |
Asset Turnover |
0.45 | 0.45 | 0.48 | 0.48 | |
Operating CF/Net income |
1.97 | 4.94 | 0.12 | 2.69 | |
Capex/Depreciation |
(1.47) | (2.28) | (1.59) | (1.57) | |
Research and Development Expense of Revenue |
18.07% | 17.06% | 15.97% | 16.02% | |
Selling, General and Administrative Expense of Revenue |
33.13% | 38.41% | 31.68% | 32.23% | |
Intangible Assets out of Total Assets |
0.22 | 0.21 | 0.23 | 0.24 | |
Share Based Compensation of Revenue |
2.65% | 2.50% | 2.75% | 2.42% | |
Graham Net Nets |
0.07 | 0.07 | 0.07 | 0.07 | |
Graham Number |
30.25 | 27.05 | 27.54 | 26.99 | |
Earnings Yield |
3.00% | 2.16% | 2.36% | 1.92% | |
Free Cash Flow Yield |
1.70% | 2.62% | 2.28% | 2.69% | |
Revenue per Share |
2.66 | 2.68 | 2.85 | 3.02 | |
Operating CF per Share |
0.98 | 0.77 | 0.08 | 1.13 | |
Capex per Share |
(0.10) | (0.17) | (0.11) | (0.12) | |
Free Cash Flow per Share |
0.88 | 0.60 | (0.04) | 1.01 | |
Cash per Share |
6.57 | 7.23 | 6.34 | 7.38 | |
Shareholders Equity per Share |
17.45 | 17.68 | 17.83 | 18.61 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.45 | 17.68 | 17.83 | 18.61 | |
Free Cash Flow |
516.20 | 353.50 | (21.10) | 585.00 | |
Working Capital |
4,770.90 | 4,925.20 | 4,819.70 | 5,311.00 | |
Capital Expenditures |
(57.50) | (97.40) | (64.90) | (66.90) | |
Net Current Asset Value |
3,291.70 | 3,379.30 | 3,235.00 | 3,676.70 | |
EV/EBIT |
30.04 | 37.04 | 32.60 | 33.88 | |
Capex to Sales |
0.04 | 0.06 | 0.04 | 0.04 | |
Price to Operating Income |
31.89 | 39.44 | 34.43 | 35.98 | |
| Other line items | |||||
Average Receivables |
852.15 | 819.75 | 862.45 | 929.15 | |
Average Payables |
168.90 | 212.45 | 176.75 | 186.30 | |
Average Inventory |
1,122.55 | 1,106.45 | 1,116.45 | 1,136.45 | |
Average Assets |
13,121.70 | 13,376.25 | 13,171.75 | 13,677.90 | |
Average Common Equity |
9,908.20 | 10,200.25 | 10,259.55 | 10,665.70 |
Columns are period end dates